You are cordially invited to join Specialist Forum and Prof Adam Reich for a discussion on the use of ixekuzumab, an injectable humanised monoclonal antibody, in the treatment of psoriasis. Ixekuzumab is indicated for the treatment of moderate-to-severe plaque psoriasis and is associated with rapid and high response rates.
This webinar is sponsored by Eli Lilly and is intended for South African-based doctors only.
Prof Reich is Head of the Department of Dermatology, as well as the Director of the Institute of Medical Sciences, University of Rzeszow, Rzeszów, Poland. He is also the Secretary General of the Polish Dermatological Society and Vice-Chair of the Youth Forum of the Polish Dermatological Society.
He completed his PhD in 2006 at the University of Medicine, Wroclaw, Poland. He is a member of the European Society for Dermatology and Psychiatry, European Society of Dermatological Research, European Academy of Dermatology and Venereology (EADV), International Forum for the Study of Itch and International Society of Dermatology.
He acts as a Section Editor for Itch/Psychology of the Journal of the European Academy of Dermatology and Venereology and the Co-Chair of the Prurigo Nodularis EADV Task Force. He is the author and/or coauthor of 176 original articles, 128 reviews and 88 case reports. He was also awarded the Prof Zdzisław Ruszczak Award for the scientific activity in psoriasis.